Kalobios Pharmaceuticals, Inc.

Varghese Palath

Christopher Robert Bebbington

Geoffrey T Yarranton

Mark Baer

Nenad Tomasevic

Kenneth Luehrsen

David Martinez

Jason Williams

Swathi Sujatha-Bhaskar

The invention provides diagnostic and therapeutic methods for the treatment of hematological proliferative disorders.

Methods of treating hematological proliferative disorders by targeting EphA3 expressed on aberrant vasculature in bone marrow

The invention provides anti-EGF-like module containing, mucin-like, hormone receptor-like 1 (EMR1) antibodies and methods of using such antibodies to treat EMR1-related diseases.

Anti-EMR1 antibodies

The invention provides methods and compositions comprising anti-EphA3 antibodies for the treatment of myeloproliferative disorders.

Treatment of leukemias and chronic myeloproliferative diseases with antibodies to EphA3

The invention is based on the discovery that GM-CSF antagonists can be used for the treatment of a patient that has Alzheimer's disease or vascular dementia, or is at risk for developing Alzheimer's disease. Accordingly, the invention provides methods of administering a GM-CSF antagonist, e.g., a GM-CSF antibody and pharmaceutical compositions comprising such antagonists.

Growing community of inventors

South San Francisco, CA, United States of America

Varghese Palath